# Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

> **NCT05272371** · PHASE1 · RECRUITING · sponsor: **Jagiellonian University** · enrollment: 20 (estimated)

## Conditions studied

- High-Risk Neuroblastoma

## Interventions

- **COMBINATION_PRODUCT:** Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)

## Key facts

- **NCT ID:** NCT05272371
- **Lead sponsor:** Jagiellonian University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05272371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05272371, "Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05272371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*